NUZ 8.11% 20.0¢ neurizon therapeutics limited

Ann: FDA Provides Clear Feedback for ODD Approval, page-143

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 12,421 Posts.
    lightbulb Created with Sketch. 6395
    Hi Aboo

    Wish I could deliver you some certainty.....

    BUT what I can do is show you Risk Reduction

    The DSMB monitored every Patient Cohort vigorously , especially as the Trial had a component of escalating doses.

    Each Cohort was screened and NO SERIOUS ADVERSE EFFECTS recognised, this allowed that Cohort to then move forward on the next increased dose.
    ( I have seen trials cancelled mid flight by the DSMB for) " No Patient Benefit" ethics does not allow Human Trials that do not demonstrate "Patient Benefit"

    PAA are fortunate to have Mathers and Rowe as our Principal Investigators , "They see 40% of all MND Patients in Australia"

    All of the Trial Patients have outlived the Disease ,Some significantly as they were diagnosed well before the trial commenced.

    The DSMB and Medical Advisory Board have allowed all Patients to remain on MPL,,, This is a NON Proven , NON FDA Approved Drug that is one of the worlds first "In Human Trial" certainly a first for the Newly Formulated Refined and Micronised PAA Tablets.
    Rowe and Mathers would be party to this occurring and with deep institutional knowledge ,understand the ramifications and consequences of such a recommendation. " Arse on line" comes to mind.

    All Patients have "wanted" to stay on the drug.

    All of the Patients are Breathing, Swallowing and Speaking ,,, "from watching MND Patients , surely not being able to speak would be terrifying and brutal"

    The easiest answer to give is "NO" and as the data analysis is ongoing as we speak "You can take solace that the current answer is Yes, the second the data shows failure then further analysis is redundant"

    What many have not calculated is that the Phase I/II results deliver far more that just MND Data , It demonstrates that PAA MPL Tablets are safe to take.
    It Demonstrates that a beneficial dose of MPL can be delivered across the Blood Brain Barrier utilising the mTOR Pathway... and that Aboo is why Big Pharma will want a slice ,, someone the size of Pfizer could fast-track Cancer , Covid Trials and Hold FDA Vouchers to put them at the top of the stack.

    Hope that helps you get some sleep,,, I'm excited , Great Results V8 , Spectacular Results V12 with 2 coats of blue unobtanium please..









 
watchlist Created with Sketch. Add NUZ (ASX) to my watchlist
(20min delay)
Last
20.0¢
Change
0.015(8.11%)
Mkt cap ! $98.34M
Open High Low Value Volume
19.0¢ 20.0¢ 19.0¢ $66.44K 346.2K

Buyers (Bids)

No. Vol. Price($)
3 86359 19.0¢
 

Sellers (Offers)

Price($) Vol. No.
20.0¢ 107894 5
View Market Depth
Last trade - 15.42pm 13/11/2024 (20 minute delay) ?
NUZ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.